Nuevolution A/S is a unique company poised to revolutionize lead discovery by utilising its proprietary Chemetics® technology to synthesize and identify hundreds of diverse drug leads to pharmaceutically important therapeutically targets.

Chemetics® represents the ultimate “convergent” fragment based lead discovery technology. It is a unique, patent protected hybrid of proven wet chemistry and molecular biology that enables the rapid synthesis and selection of ligands from millions to billions of drug-like compounds in a single test tube.


Date Type Amount Investors Valuation
06/01/12 Other 13.8M Industrifonden, Sunstone Capital, SEB Venture Capital, SEB Utvecklingsstiftelse. Unknown